3 Things That Matter Most for Eli Lilly Now

Key Points Eli Lilly has done a great job of capitalizing on its success in the GLP-1 space. Now the company has to think about what comes next. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) is a market darling, given its success in the GLP-1 weight-loss space. That's understandable, given the huge opportunity ahead in helping the world address a health issue that has such a material, and usually negative, impact on people's lives. But as you look at Eli Lilly, investors should consider these three things that are likely to matter more than you think. 1. Are Eli Lilly's GLP-1 drugs too successful? Is there such a thing as too much success? That depends on how you look at it. In the second quarter of 2026, sales of Mounjaro rose 91% year over year. Sales of Zepbound jumped 46%. And the company's newly introduced Foundayo GLP-1 pill began generating revenue. Taken together, the weight-loss drugs produced nearly $15 billion of Eli Lilly's nearly $23 billion in revenue in the quarter. That's nearly two-thirds of the company's top line. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue » Image source: Getty Images. That's a huge risk because Eli Lilly has all (OK, most) of its eggs in one single basket. Sure, that's been a very good thing so far, but eventually being so reliant on GLP-1 drugs is likely to be a problem. 2. Eli Lilly's GLP-1 growth is going to slow down (and it already is) The next big thing that investors need to understand is simple math. As a business grows, future growth becomes increasingly difficult to achieve. So the success Eli Lilly is having right now, expanding its GLP-1 business, can't last forever. In fact, the growth slowdown may already be occurring. In the second quarter of 2025, Zepbound's sales grew 172% compared to the 46% in the second quarter of 2026. To be fair, Mounjaro's growth accelerated from 68% to 91%, so there's still room to run. But trees don't grow to the sky, as the old Wall Street saying goes. 3. Eli Lilly is using its GLP-1 success wisely So Eli Lilly is seeing huge success in the GLP-1 space. That success won't last forever, given basic math, the highly competitive nature of the pharmaceutical industry , and the finite duration of drug patents. Which brings up another big opportunity and risk. Eli Lilly has been aggressively using its GLP-1 success to fund acquisitions that expand its business into new treatment areas. That's a wise move, so investors should be pleased with management. However, developing new treatments is time-consuming, difficult, and sometimes new drug candidates don't work out. So Eli Lilly is doing the right thing given the situation, but that doesn't mean it will result in long-term success for the business. Three big-picture issues to watch at Eli Lilly If you are looking at Eli Lilly today, three things to monitor are the sheer size of the GLP-1 business, its growth rate, and the company's efforts to expand beyond the weight-loss market. If you only see the success the company is achieving, you could end up surprised when the GLP-1 story eventually starts to look less positive. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $440,710 !* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,335,252 !* Now, it’s worth noting Stock Advisor’s total average return is 978 % — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor , and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of August 29, 2026. Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool has a disclosure policy .

Eli Lilly has done a great job of capitalizing on its success in the GLP-1 space.

Eli Lilly (NYSE: LLY) is a market darling, given its success in the GLP-1 weight-loss space. That's understandable, given the huge opportunity ahead in helping the world address a health issue that has such a material, and usually negative, impact on people's lives. But as you look at Eli Lilly, investors should consider these three things that are likely to matter more than you think.

Is there such a thing as too much success? That depends on how you look at it. In the second quarter of 2026, sales of Mounjaro rose 91% year over year. Sales of Zepbound jumped 46%. And the company's newly introduced Foundayo GLP-1 pill began generating revenue. Taken together, the weight-loss drugs produced nearly $15 billion of Eli Lilly's nearly $23 billion in revenue in the quarter. That's nearly two-thirds of the company's top line.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

That's a huge risk because Eli Lilly has all (OK, most) of its eggs in one single basket. Sure, that's been a very good thing so far, but eventually being so reliant on GLP-1 drugs is likely to be a problem.

The next big thing that investors need to understand is simple math. As a business grows, future growth becomes increasingly difficult to achieve. So the success Eli Lilly is having right now, expanding its GLP-1 business, can't last forever. In fact, the growth slowdown may already be occurring. In the second quarter of 2025, Zepbound's sales grew 172% compared to the 46% in the second quarter of 2026. To be fair, Mounjaro's growth accelerated from 68% to 91%, so there's still room to run. But trees don't grow to the sky, as the old Wall Street saying goes.

So Eli Lilly is seeing huge success in the GLP-1 space. That success won't last forever, given basic math, the highly competitive nature of the pharmaceutical industry , and the finite duration of drug patents. Which brings up another big opportunity and risk. Eli Lilly has been aggressively using its GLP-1 success to fund acquisitions that expand its business into new treatment areas.